|
Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial. |
|
|
|
Consulting or Advisory Role - Bayer; Calithera Biosciences; GlaxoSmithKline; Natera; Novartis |
Research Funding - Bristol-Myers Squibb; Pfizer |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma |
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis |
Research Funding - CGI; Novartis; Pfizer |
|
|
Employment - Mesoblast (I); Novartis |
Stock and Other Ownership Interests - Novartis |
|
|
Consulting or Advisory Role - Eisai; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |